UCHL1 and myeloid sarcoma: This study is the first, that showed the possibility of UCHL1 being a promising high-sensitive potential biomarker of RRMS, especially since the sensitivity of plasma UCHL1 concentration evaluation in differentiating MS patients from healthy individuals was very high (100%).